Prevnar 13®
As virtual in-house counsel to Wyeth Vaccines, provided on-site patent counsel services for their NC-based research and manufacturing facilities, including seminal patent prosecution and worldwide portfolio management services for Prevnar 13® (the world's best-selling vaccine before COVID-19, with over $55 Billion in sales since 2010). Pfizer acquired Wyeth in 2009 for $68 Billion, in large part due to Wyeth's vaccine and biologics portfolios. Selected patent application samples are provided below.
WO2008079732.pdf
WO2008079732 - MULTIVALENT PNEUMOCOCCAL POLYSACCHARIDE-PROTEIN CONJUGATE COMPOSITION (produced multiple issued patents around the world including US Patent Nos. 7709001, 7955605, and 8895024).
WO2008045852.pdf
WO2008045852 - PURIFICATION OF STREPTOCOCCUS PNEUMONIAE TYPE 3 POLYSACCHARIDES (produced multiple issued patents around the world including US Patent No. 7659090).
WO2006110352.pdf
WO2006110352 - SEPARATION OF CONTAMINANTS FROM STREPTOCOCCUS PNEUMONIAE POLYSACCHARIDE BY PH MANIPULATION (produced multiple issued patents around the world including US Patent No. 7718791).
